Global Dermatology Partnering 2016-2023: Deal trends, players and financials
The Global Dermatology Partnering 2016-2023 report provides comprehensive understanding and unprecedented access to the dermatology partnering deals and agreements entered into by the worlds leading healthcare companies
The Global Dermatology Partnering 2016-2023: Deal trends, players and financials report provides an understanding and access to the dermatology partnering deals and agreements entered into by the worlds leading healthcare companies.
- Trends in dermatology partnering deals
- Financial deal terms for headline, upfront and royalty by stage of development
- Dermatology partnering agreement structure
- Dermatology partnering contract documents
- Top dermatology deals by value
- Most active dermatology dealmakers
Most of the deals included within the report occur when a licensee obtains a right or an option right to license a licensor’s product or technology. More often these days these deals tend to be multi-component including both a collaborative R&D and a commercialization of outcomes element.
The report takes readers through the comprehensive dermatology disease deal trends, key players and top deal values allowing the understanding of how, why and under what terms companies are currently entering dermatology deals.
The report presents financial deal terms values for dermatology deals, where available listing by overall headline values, upfront payments, milestones and royalties enabling readers to analyse and benchmark the value of current deals.
The initial chapters of this report provide an orientation of dermatology dealmaking trends.
Chapter 1 provides an introduction to the report.
Chapter 2 provides an overview of the trends in dermatology dealmaking since 2016 covering trends by year, deal type, stage of development, technology type and therapeutic indication.
Chapter 3 includes an analysis of financial deal terms covering headline value, upfront payment, milestone payments and royalty rates.
Chapter 4 provides a review of the leading dermatology deals since 2016. Deals are listed by headline value. The chapter includes the top 25 most active dermatology dealmakers, together with a full listing of deals to which they are a party. Where the deal has an agreement contract published at the SEC a link provides online access to the contract.
Chapter 5 provides comprehensive access to dermatology deals since 2016 where a deal contract is available, providing the user with direct access to contracts as filed with the SEC regulatory authorities. Each deal title links via Weblink to an online version of the deal record contract document, providing easy access to each contract document on demand.
Chapter 6 provides a comprehensive directory of all dermatology partnering deals by specific dermatology target announced since 2016. The chapter is organized by specific dermatology therapeutic target. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.
In addition, a comprehensive appendix is provided with each report of all dermatology partnering deals signed and announced since 2016. The appendices are organized by company A-Z, stage of development at signing, deal type (collaborative R&D, co-promotion, licensing etc) and technology type. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.
The report also includes numerous tables and figures that illustrate the trends and activities in dermatology partnering and dealmaking since 2016.
In conclusion, this report provides everything a prospective dealmaker needs to know about partnering in the research, development and commercialization of dermatology technologies and products.
Contract documents provide the answers to numerous questions about a prospective partner’s flexibility on a wide range of important issues, many of which will have a significant impact on each party’s ability to derive value from the deal.
Global Dermatology Partnering 2016-2023 is intended to provide the reader with an in-depth understanding and access to dermatology trends and structure of deals entered into by leading companies worldwide.
Global Dermatology Partnering 2016-2023 includes:
- Trends in dermatology dealmaking in the biopharma industry since 2016
- Access to headline, upfront, milestone and royalty data
- Access tohundreds of dermatology deal contract documents
- Access to dermatology deal records
- The leading dermatology deals by value since 2016
- Most active dermatology dealmakers since 2016
The report includes deals for the following indications: Acne, Actinic keratosis, Angioedema, Burns, Cellulitis, Cosmetics, Dermatitis, Diabetic foot ulcer, Eczema, Hair disorders, Alopecia, Impetigo, Itching, Nail disorders, Psoriasis, Rosacea, Scabies, Sun damage, Rash, Scar, Venous ulcer, Verruca, Wound healing, Wrinkles, plus other dermatology indications.
In Global Dermatology Partnering 2016-2023, the available deals are listed by:
- Company A-Z
- Headline value
- Stage of development at signing
- Deal component type
- Specific therapy target
Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.
The Global Dermatology Partnering 2016-2023 report provides comprehensive access to available deals and contract documents for dermatology deals. Analyzing actual contract agreements allows assessment of the following:
- What are the precise rights granted or optioned?
- What is actually granted by the agreement to the partner company?
- What exclusivity is granted?
- What is the payment structure for the deal?
- How are the sales and payments audited?
- What is the deal term?
- How are the key terms of the agreement defined?
- How are IPRs handled and owned?
- Who is responsible for commercialization?
- Who is responsible for development, supply, and manufacture?
- How is confidentiality and publication managed?
- How are disputes to be resolved?
- Under what conditions can the deal be terminated?
- What happens when there is a change of ownership?
- What sublicensing and subcontracting provisions have been agreed?
- Which boilerplate clauses does the company insist upon?
- Which boilerplate clauses appear to differ from partner to partner or deal type to deal type?
- Which jurisdiction does the company insist upon for agreement law?
Global Dermatology Partnering 2016 to 2023 provides the reader with the following key benefits:
- In-depth understanding of dermatology deal trends since 2016
- Access dermatology deal headline, upfront, milestone and royalty data
- Research hundreds of actual contracts between dermatology partner companies
- Comprehensive access to links to actual dermatology deals entered into by the world’s biopharma companies, together with contract documents if available
- Indepth review of dermatology deals entered into by the top 25 most active dealmakers
- Benchmark the key deal terms companies have agreed in previous deals
- Identify key terms under which companies partner dermatology opportunities
- Uncover companies actively partnering dermatology opportunities
Chapter 1 – Introduction
Chapter 2 – Trends in dermatology dealmaking
2.2. Dermatology partnering over the years
2.3. Dermatology partnering by deal type
2.4. Dermatology partnering by industry sector
2.5. Dermatology partnering by stage of development
2.6. Dermatology partnering by technology type
2.7. Dermatology partnering by therapeutic indication
Chapter 3 –Financial deal terms for dermatology partnering
3.2. Disclosed financials terms for dermatology partnering
3.3. Dermatology partnering headline values
3.4. Dermatology deal upfront payments
3.5. Dermatology deal milestone payments
3.6. Dermatology royalty rates
Chapter 4 – Leading dermatology deals and dealmakers
4.2. Most active in dermatology partnering
4.3. List of most active dealmakers in dermatology
4.4. Top dermatology deals by value
Chapter 5 – Dermatology contract document directory
5.2. Dermatology partnering deals where contract document available
Chapter 6 – Dermatology dealmaking by therapeutic target
6.2. Deals by dermatology therapeutic target
Appendix 1 – Directory of dermatology deals by company A-Z since 2016
Appendix 2 – Directory of dermatology deals by deal type since 2016
Appendix 3 – Directory of dermatology deals by stage of development since 2016
Appendix 4 – Directory of dermatology deals by technology type since 2016
Further reading on dealmaking
Deal type definitions
About Wildwood Ventures
Recent report titles from CurrentPartnering
Table of figures
Figure 1: Dermatology partnering since 2016
Figure 2: Dermatology partnering by deal type since 2016
Figure 3: Dermatology partnering by industry sector since 2016
Figure 4: Dermatology partnering by stage of development since 2016
Figure 5: Dermatology partnering by technology type since 2016
Figure 6: Dermatology partnering by indication since 2016
Figure 7: Dermatology deals with a headline value
Figure 8: Dermatology deals with upfront payment values
Figure 9: Dermatology deals with milestone payment
Figure 10: Dermatology deals with royalty rates
Figure 11: Active dermatology dealmaking activity since 2016
Figure 12: Top dermatology deals by value since 2016
- $3,995: single-user
- $5,745: multi-user
- $10,995: single site license
- $17,995: global site license
A full explanation of license type definitions can be found here.
We guarantee our prices are competitive. If you find the same report advertised at a lower price within 7 days of purchase, we will refund the difference.
We guarantee that the report will be sent within the specified delivery times. In the unlikely case of a delay we may offer a partial refund as compensation. (Terms may apply)
If an update is published within 30 days of your purchase, you will receive it absolutely free of charge.
All card payments are processed by SagePay.
If you have any questions about your report or are unhappy with the quality, we will do our best to resolve your query. Contact us direct.
- Total Trust
Current Partnering is part of Wildwood Ventures Ltd., based in York, United Kingdom. We have been trading successfully online since 2009 and work with some of the most famous brands in the business. We carefully select our partners to ensure that the publications meet expectations of demanding customers.
3Derm Systems, 3M, 23andMe, Abacus Health Products, Abbvie, ABIGO Medical, Ablexis, AccuTec Blades, Acelity, Acell, Acera Surgical, Acino Pharma, Aclaris Therapeutics, Adalvo, Adaptive Phage Therapeutics, Adhesys Medical, adMare BioInnovations, Advanced Human Imaging, Advanced Medical Solutions, Advanz Pharma, Advonex, Aesthetic Management Partners, Aesthetic Solutions, AFT Pharmaceuticals, Aghraas-Cigalah, AiCuris, AiVita Biomedical, Ajinomoto Bio-Pharma Services, Akaal Pharma, ALASTIN Skincare, Alat Medika Indonesia, Albany Molecular Research, Alibaba Health, AlivaMab Discovery Services, ALK-Abello, Allderma, Allergan, Allergan Aesthetics, Alliance Pharma, Alliqua Biomedical, AlloSource, AllSpire Health, Almirall, Altaris Capital Partners, Alvotech, American Medical Technologies, American Skin Association, Amgen, AMI, AMNIOX, Amor (Suzhou) Medical Sci-Tech, AMSilk, Amyris, Amytrx Therapeutics, Anacor Pharmaceuticals, ANANDA Scientific, Angelini Pharma, AnGes MG, Anhalt University of Applied Sciences, ANI Pharmaceuticals, Anlicare International, Antares Pharma, Anterios, Antibe Therapeutics, AntibioTx, AOTI, Aphex BioCleanse Systems, APL, Applied Biology, APR Applied Pharma Research, Apria Healthcare Group, Aquavit Pharmaceuticals, Aralez Pharmaceuticals, Arcaea, Arch Biopartners, Arch Therapeutics, Arctic Therapeutics, Arcutis Biotherapeutics, argenx, Arjo, Arrevus, Arrien Pharmaceuticals, Art of Technology, Asana Biosciences, Asia Green Biotechnology, Aslan Pharma, Assertio Therapeutics, AstraZeneca, ATG Allied Technologies, Athenex, Atropos Therapeutics, Aucta Pharmaceuticals, Aurealis Therapeutics, Avalon Pharmaceuticals, Avaria Health & Beauty, Avicanna, AVIR Pharma, Avita Medical MENA, Avita Therapeutics, AvKARE, Avra, Axcelon Dermacare, Axonlab, Axxess Pharma, Azitra, Back-A-Line, Bandgrip, BASF, Basilea Pharmaceutica, Bausch & Lomb, Bavarian Ministry for Economic Affairs and Media, Energy and Technology, Baxalta, Bayer, Beiersdorf, Beijing InnoCare Pharma, Belle.ai, Bellus Health, Ben-Gurion University, Berkshire Sterile Manufacturing, Best Choice, BGN Technologies, Bill and Melinda Gates Foundation, BinnoPharm, Bio-Gate, BioAesthetics, Biocogent, Biocon, BioCryst Pharmaceuticals, BioDerm, Biogen, Biohaven Pharmaceuticals, BioLab Sciences, Biomedical Advanced Research and Development Authority, BIOMEDX Group, BioMed X Innovation Center, Biometrix, Biomillenia, BiomX, Bioniz Therapeutics, Bionpharma, BioPep, Biophage Pharma, BiopharmX, Bioqube Ventures, BiosanaPharma, Bioskin, Biosolution, BioStem Technologies, Biosynthetic Technologies, BirchBioMed, BMG Pharmaceuticals, Boehringer Ingelheim, Bone Medical, Boragen, Boston Pharmaceuticals, Boston Topicals, Botanix Pharmaceuticals, BoyaLife, Brickell Biotech, Brigham and Women's Hospital, Bright Future Pharmaceutical Lab, Brown University, Bruin Biometrics, Buffalo Supply, Cadila Pharmaceuticals, CALECIM Cosmeceuticals, California Institute for Regenerative Medicine, Camargo Pharmaceutical Services, Can-Fite BioPharma, CANbridge Pharmaceuticals, Candela, CannaSkin, Cannassure Therapeutics, Cannaworx, CanniMed Therapeutics, Canopy Growth, Cap Alter Pharma, Capital Laser and Skin Care, Capstone Health Alliance, Cara Therapeutics, CARB-X, Cardiome Pharma, Cardiovascular Systems, CarePICS, Carestream Health, Cassiopea, Celgene, CellMark Medical, Cell Mogrify, Celularity, Centurion Therapeutics, Certara, Ceva Sante Animale, Chelexa Biosciences, Chemstar, Children's Hospital Boston, China-Israel Biological Technology, China National Biotech Group (CNBG), Chongqing Jingdong Pharmaceutical, Chromaderm, Chugai Pharmaceutical, Cilag AG, Cipher Pharmaceuticals, Cipla, Circadia, CIVCO Radiotherapy, CJ CheilJedang, Clarify Medical, Clinuvel Pharmaceuticals, CMS Aesthetics, CMS Medical, Codex Beauty, Collagen Solutions LLC, Collplant, Columbia University Medical Center, ConvaTec, Cook Biotech, Cooper-Vemedia, Corza Health, Cosmofix, Cosmotec, Costa Brazil, Covalon Technologies, Creabilis Therapeutics, Crescita Therapeutics, CROMA Pharma, Cronos Group, Crown Laboratories, Cryolife, Cumberland Pharmaceuticals, CURE Pharmaceutical, Curetis, Curzion Pharmaceuticals, Cutanea Life Sciences, Cutia Therapeutics, Cynata Therapeutics, Cytori Therapeutics, CytoSorbents, Dabur, Daewoong Pharmaceutical, Dalhousie University, Daniel Alain Life Science, DASH Analytics, Daxor, Dechra Pharmaceuticals, Defense Health Agency (US), Denali Therapeutics, Department of Defense, Department of Veterans Affairs, DermaConcepts, DERMAdoctor, Dermala, DermapenWorld, Dermasilk, Dermavant Sciences, DermBiont, Dermelix Biotherapeutics, Dermira, DermOQ, Dermpath Diagnostics, DermTech, Devonian Health Group, Digital Diagnostics, Dignitana, Diplomat, DKSH, Dong-A ST, Dow Pharmaceutical Sciences, Dr. Reddy's Laboratories, Dr. U Devices, Draper Laboratories, Dr Bragi Company, Dr Kerklaan Therapeutics, DS Biopharma, DS Healthcare, DSM Nutritional Products, Ducere Pharma, Dyamed Biotech, Dynamic Blending, Dynasil, Easton Pharmaceuticals, EB Research Foundation, EB Research Partnership, Eclipse Aesthetics, ECMOHO, Edesa Biotech, Egis, Eirion Therapeutics, Eisai, eKare, Ekpac Healthcare, Elanix Biotechnologies, Elektrofi, Elev8 Brands, Elevai Labs, Eligo Bioscience, Eli Lilly, Ember Therapeutics, EMC, Emergent BioSolutions, Emmaus Life Sciences, Emollivet, Emphysys, EMS, Encore Dermatology, Encore Medical, Endo International, Enteris Biopharma, Enzymatica, Epicore Biosystems, EPI Health, EQT, Equillium, Er-Kim, Espada Dermatology, EspeRare Foundation, Essity, Estee Lauder, Ethicon Endo-Surgery, Eureka Eurostars, Eurofins Scientific, European Wellness Biomedical Group, Eve & Co, Evolve BioSystems, Evommune, Evotec, Ewopharma, ExCEEd Orphan, Excelra, Exicure, Expanscience, EZbra Advanced Wound Care, Fagron, Farco Pharma, Felix Biotechnology, Fillmed, First Horizon Pharmaceuticals, FirstString Research, Fission Labs LATAM, Flowerkist, Foamix Pharmaceuticals, FormaTK Systems, Forte Biosciences, Fosun Pharmaceutical, Frost Pharma, Fujifilm Kyowa Kirin Biologics, Fuji Pharma, Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau, Fuse Medical, Gadusol Laboratories, Galapagos, Galderma, Gale Force Aesthetics, Gebro Pharma, Geisel School of Medicine at Dartmouth, Gel4Med, Gene Biotherapeutics, Genentech, GenesisCare, Genfa Medica, Genome BC, George Washington University, Ghassan Aboud Group, Ginkgo BioWorks, Givaudan, GlaxoSmithKline, GL Brands, GlobalMed, GPC Systems, Grove Collaborative, Grunenthal, GtreeBNT, Guangzhou Xiangxue Pharmaceutical, Gunze, Guthy-Renker, H-CYTE, H2-Pharma, Hairmore Group, Happify Health, Harmony Hemp, Harvard Medical School, Hawkeye Therapeutics, Healiant, Healiva, Helsinn Healthcare, HemCon Medical Technologies, Hemostasis, Henry M. Jackson Foundation, Henry Schein, Herbs Of Kedem, Heumann Pharma Generics, High Beauty, Hill Dermaceuticals, Histapharm, Histogen, HitGen, Hollister Biosciences, Hope Medicine, Horizon Therapeutics, Hoth Therapeutics, Houston Methodist Research Institute, HS Pharmaceuticals, HTDK Group, Huapont Pharma, Hume Supernatural, Huons, Hydrofera, Hyloris Pharmaceuticals, Hyphens, Iagnosis, Icahn School of Medicine at Mount Sinai, Ice + Jam, Ichnos Sciences, IDEAYA Biosciences, IlmixGroup, Imbed Bio, IME Medical Electrospinning, IMIDomics, Immunomic Therapeutics, Incyte, Indipharm, Induce Biologics, Infinivive, InfuSystem Holdings, Innate Biologics, Innovate UK, Innovation Skane, Innovative Cellular Therapeutics, Innovent Biologics, Innovize, Innovus Pharmaceuticals, Inova Diagnostics, Intalere, Intas Pharmaceuticals, INTEGA Skin Sciences, Integra LifeSciences, Integumen, Interpolymer/Zschimmer & Schwarz, Intralytix, IQVIA, iS Clinical, ISDIN, Isoprene Pharmaceuticals, Jabil Circuit, Jackson Laboratory, James Cook University, Janssen Biotech, Janssen Pharmaceuticals, Janssen Pharmaceutica NV, Janssen Research & Development, Janssen Therapeutics, Japan Tobacco, JCR Pharmaceuticals, Jeune, Jiangsu Hengrui Medicine, Jiangsu QYuns Therapeutics, Joerns Healthcare, Johns Hopkins University, Johnson & Johnson, Johnson & Johnson Consumer Companies, Johnson & Johnson Innovation, Journey Medical, JT Pharmaceuticals, Juntendo University, Jupiter Wellness, JuvenIL, Juyou Biotechnology, JW Pharmaceutical, Kaken Pharmaceutical, Kaleido Biosciences, Kane Biotech, Karo Pharma, Keck School of Medicine of USC, Kensing, Kent Imaging, Keraderm, Kerecis, King's College Hospital, Kiniksa Pharmaceuticals, KiOmed Pharma, Kleresca, KNOW Bio, Kramer Laboratories, Krystal Biotech, Kubota Vision, Kuria Therapeutics, Kyocera, Kyongbo Pharm, Kyowa Hakko Kirin, L&P Cosmetic, L'Oreal, Lactobio, Lannett, Laser Clinics Australia, Laser Lab Corp, Lautus Pharmaceuticals, Legacy Biotechnologies, Leiden University, Lenus Therapeutics, Leon-nanodrugs, LEO Pharma, LGC, LifeMax Laboratories, Ligand Pharmaceuticals, Lighthouse Strategies, Lipidor, LipoTrue, Loreal, Lovell Government Services, Lubrizol, Luminera, Lupin, Luqa Pharmaceuticals, Lutris Pharma, Lygos, Lysando, Mabwell Bioscience, MainPointe, Makromed, Mallinckrodt Pharmaceuticals, Mamba Instruments, MannKind Biopharmaceuticals, Maplex Naturals, Maren Cosmetics, Maruho, Massachusetts General Hospital, Massachusetts Life Sciences Center, Massage Envy, MatriSys Bioscience, Maxhealth Medicine, Mayne Pharma, MC2 Therapeutics, McMaster University, MDS Pharma Services, Meabco, Med-Aesthetic Solutions, Medcura, Medela, Medicamat, Medimetriks, MediPharm Labs, Mediq, MediWound, Medline Industries, MedPharm, MedShape, Medshift, Medx, Meiji Seika, MellingMedical, MEME, Menarini, Menlo Therapeutics, Merakris Therapeutics, Merck KGaA, Merz, Mesoblast, Metalabs, Metaoptima Technology, Metrion Biosciences, Michelson Diagnostic, Michepro, Micreos, Microbio Shanghai, MicroCures, MiMedx, MiNDERA, Mintcare, Miravo Healthcare, Mirum Pharmaceuticals, Misonix, Mitsubishi Tanabe Pharma, Moberg Pharma, MolecuLight, Molnlycke Health Care, Momenta Pharmaceuticals, Monash University, MoonLake Immunotherapeutics, MorphoSys, MSM-Medimpex, MT.DERM, MTF Biologics, Mundimed, Mundipharma, MWMedical, MyBiotics Pharma, Mylan Pharmaceuticals, MyungMoon Bio, Nabriva Therapeutics, Nanning Xinzizhu Trading, NanoVibronix, NassifMD Dermaceuticals, National Eczema Association, National Institute of Allergy and Infectious Diseases, National Institute of Arthritis and Musculoskeletal Diseases, National Institute of Diabetes and Digestive and Kidney Diseases, National Institute of General Medical Sciences, National Institutes of Health, National Psoriasis Foundation, National Research Council Canada, National Research Council of Canada, National Science Foundation, Nationwide Laboratory Services, Neograft Technologies, NEO Tech, Neptune Wellness Solutions, Nestle, Net Health Systems, NewSurg, New York University School of Medicine, Nexcure Pharma, NexGen Medical Systems, Nextech Systems, Nextmune, Nikkol, No BS Skincare, Nogra Pharma, Nordic Pharma Group, North Carolina State University, Northwestern University, NovaBay Pharmaceuticals, Novan, Novan Therapeutics, Novartis, Novelty Nobility, Now Biopharma, Nuevolution, Nuo Therapeutics, Nutech Medical, Nutriband, Nuvothera, Oakrum Pharma, Obagi Cosmeceuticals, Obagi Medical Products, Oklahoma Medical Research Foundation, Olaregen Therapeutix, Olika, OliX Pharmaceuticals, OncoBeta, Oncodesign, Oneness Biotech, ON Light Sciences, OptiBiotix, Or-Genix Therapeutics, Orchard Therapeutics, Organogenesis, Organ Technologies, ORIG3N, Origimm Biotechnology, Orphan Europe, Orpharm, Osiris Therapeutics, Otsuka, Ovation Science, OWC Pharmaceutical Research, Padagis, Paladin Labs, Palisade Bio, Palobiofarma, Palvella Therapeutics, Paratek Pharmaceuticals, Particle Sciences, PathogenDx, Patient-Centered Outcomes Research Institute, PCG Clinical Services, PDL BioPharma, Pediatric Dermatology Research Alliance, Pediatrix Therapeutics, PellePharm, Pelle Ventures, Perrigo, Perry Baromedical, Peterson's Lab, Pfizer, Pharmacyna, PharmaResearch Products, Pharming Group, PhaseOne Health, Phosphagenics, PhotoMedex, Phyto Tech, Piedmont Pharmaceuticals, Pierre Fabre, Pierre Fabre Dermatologie, Pint Pharma, Piqur Therapeutics, Plyzer Technologies, Podimetrics, PolarityTE, Popit, Portola Pharmaceuticals, Precision Healing, Premier Inc, Prescient Surgical, Prime Therapeutics, Priovant Therapeutics, Prism Medical Products, Promius Pharma, Promore Pharma, Proscia, Protagen, Protagonist Therapeutics, Proya Cosmetics, Psilocin Pharma, Pura Naturals, Purdue Pharma, PureKana, Pure Med Farma, Purnovate, Pyramid Biosciences, Queensland University of Technology, Quest Products, Quoin Pharmaceuticals, RAHN, Ra Medical Systems, Randob Labs, Rapid Dose Therapeutics, Rational Surgical Solutions, Realm Therapeutics, Reckitt Benckiser, Red One Medical, Reedy Creek Investments, Regenerative Biologics, Regenerative Medicine of China, Regenerative Medicine of Latin America, Regenicin, Regis Technologies, Rehabtronics, ReLeaf Europe, Relief Therapeutics, Relife, Renovacare, Repertoire Immune Medicines, Replicel Life Sciences, Repurpose.AI, Resilia Pharmaceuticals, Restorix Health, Revance Therapeutics, Revision Skincare, Revive Therapeutics, Rigour International, RIKEN Yokohama Institute Omics Science Center, Rochal Industries, Roche, Rodan and Fields, ROi (Resource Optimization & Innovation), Roivant Sciences, Royalty Pharma, RVL Pharmaceuticals, Safe Sea, SaltMED, Salus Medical, Samsung Bioepis, Samsung Biologics, Samumed, Sanara MedTech, Sandoz, Sanmina, Sanofi, Sanpellegrino Cosmetics, Sanuwave Health, Saraya, SastoMed, Satiogen Pharmaceuticals, Sato Pharmaceutical, Scapa Healthcare, Schweiger Dermatology Group, SciBase, Science 37, Scion Solutions, Sciton, Scohia Pharma, Sebacia, Second Genome, Sensus Healthcare, SenzaGen, Seqirus, Sequence Bio, SerenaGroup, Shanghai Corday Biotech, Shanghai Haohai Biological Technology, Shire Pharmaceuticals, Sienna Biopharmaceuticals, Signum Biosciences, Simris Biomimetics, Sinclair Pharmaceuticals, Sincopharm, Sinopharm, Sinovant Sciences, Sirenas, Sirona Biochem, sk:n, SkinBiotix, Skincential Sciences, SkinDisc, Skin Products, SkinScience Labs, SkinSciPac, Skinvisible, SMG Pharmaceuticals, Smith & Nephew, Societal CDMO, Sofwave Medical, Sol-Gel, Soliton, Solomomo, Soluble Systems, Sonoma Pharmaceuticals, Sosei Heptares, Southmedic, Southwest Transplant Alliance, Spartan Medical, Spear Pharmaceuticals, Specialty Therapeutics PC, Spenta, Spherix, Springs Rejuvenation, StemCell Systems, Sternlaser Medical Aesthetics Solutions, STRATA Skin Sciences, Stratatech, Stratpharma, Sumitomo Chemical Company, Summit Pharmaceuticals / Alliance Labs, Sun Capital Partners, Sundaily, Sun Pharmaceutical, Surrozen, SutroVax, Swedish Bactiguard, Swift Medical, Swiss Institute of Allergy and Asthma Research, Swixx Biopharma, SWK Funding, Swysh, SYnergy Medsales, Syneron Medical, Systagenix Wound Management, Taiho, Takeda Pharmaceutical, Tauriga Sciences, Teb Sanaat Lotus, Tec-Pharm, Tec-Pharma, TechCare, Technion Research and Development Foundation, TekCyte, Tela Bio, Telemedicine Solutions, Terumo Cardiovascular Systems, The HydraFacial Company, The Innovation Fund, TheraLight, Theravant, TheraVida, ThermiGen, Thermo Fisher Scientific, Thirona Bio, Thomas Jefferson University, Thought Leadership & Innovation Foundation, Timber Pharmaceuticals, Tissue Analytics, Tissue Regenix, Titan Pharmaceuticals, Tocagen, Torii Pharmaceutical, TouchMD, Triage Technologies, TrialSpark, Tricol International, Trinnovations, Tulane University, Turn Therapeutics, TWi Biotechnology, Tyris Therapeutics, uBiome, Uluru, Uni-Bio Science, Uniformed Services University of the Health Sciences, UNION Therapeutics, Univar, University of Alabama at Birmingham, University of Barcelona, University of California, San Diego, University of California, San Diego (UCSD) School of Medicine, University of California Los Angeles, University of California San Francisco, University of Cincinnati, University of Colorado, University of Colorado Denver, University of Dundee, University of Manchester, University of Maryland Baltimore, University of Massachusetts, University of New Mexico, University of North Carolina, University of Oxford, University of Pennsylvania, University of Pittsburgh, University of South Australia, University of Virginia, University of Washington, University of Wisconsin, Upside Biotechnologies, Urgo Laboratories, USANA Health Science, US Army, US Army Institute of Surgical Research (USAISR), US Army Medical Research and Material Command, Valeant Pharmaceuticals, ValenzaBio, Vanderbilt University, Vasomune Therapeutics, Vaxcyte, Velocity Fund Partners, Venturis Therapeutics, Vericel, Verily, Verrica Pharmaceuticals, Veterans Medical Distributors, VHA, ViaDerma, Victoria University, VidaCeuticals Health Products, Vifor Pharma, Villaris Therapeutics, Vipergen, VisionQuest Biomedical, Visualant, VisualDx, Vitae Naturals, Vitae Pharmaceuticals, Vitamed Biomedical, Vitro Biopharma, Vitruvias Therapeutics, Vizient, Vogue, Voronoi, VYNE Therapeutics, Warmuth Institute of Dermatology, Wearifi, Weihai Weigao Medical Devices, Weill Cornell Medical College, Wellness Center USA, West Dermatology, Winhealth Pharma Group, Winner Medical Group, Wistar Institute, Wockhardt, Worcester Polytechnic Institute (WPI), Worldwide Clinical Trials, Wound Care Advantage, Wuhan Miracle Laser Systems, WuXi Biologics, X-chem, Xbiome, XBiotech, Xcede Technologies, Xcelerate Solutions, XCellR8, Xoma, Xycrobe Therapeutics, Yale School of Medicine, YOFOTO (China) Health Industry, Young Pharmaceuticals, YuYang DNU, YuYu Pharma, ZappRx, Zenoaq, Zentiva, Zhejiang Longterm Medical, Zhittya Genesis Medicine, Ziarco Pharma, Zikad International Aesthetics Supplier, Zuellig Pharma China, Zymetech, Zymeworks
Current Partnering reports provide insight into the trends and terms of partnering deals in the global life sciences sector.
Current Partnering reports are updated every six months to ensure the user has access to the latest announcements and trends in the topic focus of the report.
Current Partnering analysts review the deal data to provide an overview and analysis of deal trends, including example deals and terms.
Current Partnering reports source deal data from our proprietary deals and alliances database, Current Agreements. The database is updated daily by our analysts with new deals as they are announced globally by the company’s party to the deal. In addition, deal records are updated with new data as it becomes available.
The data in the Current Agreements deals and alliances database is obtained from secondary sources such as publicly available industry sources including press releases, company presentations, investor presentations, company SEC filings, other company filings, company websites, conference presentations. Sources are identified to allow for user verification.
Current Partnering provides comprehensive coverage of the following partnering or deal types:
• Asset purchase
• Collaborative R&D
• Contract service
• Equity purchase
• Joint venture
• Royalty financing
• Spin out
• Sub license
Every deal record is fully categorized and includes the following data, where available:
• Industry sector
• Therapy areas
• Technology type
• Deal components
• Financial terms
• Stage of development
• Asset type
• Geographic focus
• Excluded geography
• Company press release
• SEC filing data including contract document
All financial amounts are converted to US$ using the exchange rate available on the date of deal announcement, enabling direct comparison of deal terms across international territories.
Financial data and contract documents displayed in deal records is obtained from public sources, where disclosed by the parties to the deal.